⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

November 26, 2003Journal of Clinical Oncology

Treatment of Plasma Cell Dyscrasias With Thalidomide and Its Derivatives

View Full Paper

Ask AI

Bookmark

Share

Authors

Meletios Α. DimopoulosAlexandra Hospital ΑAΑchilles AnagnostopoulosG. Papanikolaou General Hospital DWDonna WeberThe University of Texas MD Anderson Cancer Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Dimopoulos et al. (2003) studied this question.

synapsesocial.com/papers/69d817eba2a48916bbbeef69 https://doi.org/10.1200/jco.2003.07.200

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

1DTPACE: An Effective, Novel Combination Chemotherapy With Thalidomide for Previously Treated Patients With Myeloma2003 · 175 citations
2Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients2001 · 543 citations
3Thalidomide: Emerging Role in Cancer Medicine2002 · 140 citations
4Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production.1996 · 118 citations